Find Out: How to Find One Stock with Crorepati Potential?
Here is the latest financial fact sheet of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA quarterly results and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.2 |
No. of shares | m | 196.56 |
1 Week | % | 0.1 |
1 Month | % | -4.5 |
1 Year | % | -26.0 |
52 week H/L | Rs | 1,015.9/672.0 |
No. of Mths Year Ending |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
5-Yr Chart Click to enlarge
|
---|
ALEMBIC PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 709 | 645 | 664 | 683 | 1,150 | |
Low | Rs | 516 | 470 | 412 | 435 | 527 | |
Sales per share (Unadj.) | Rs | 166.3 | 166.1 | 208.7 | 244.3 | 274.4 | |
Earnings per share (Unadj.) | Rs | 21.6 | 22.3 | 31.4 | 42.5 | 56.7 | |
Diluted earnings per share | Rs | 20.7 | 21.4 | 30.1 | 40.7 | 56.7 | |
Cash flow per share (Unadj.) | Rs | 26.0 | 27.9 | 37.5 | 50.8 | 66.0 | |
Dividends per share (Unadj.) | Rs | 4.00 | 4.00 | 5.50 | 10.00 | 14.00 | |
Adj. dividends per share | Rs | 3.84 | 3.84 | 5.27 | 9.59 | 14.00 | |
Avg Dividend yield | % | 0.7 | 0.7 | 1.0 | 1.8 | 1.7 | |
Book value per share (Unadj.) | Rs | 100.9 | 117.8 | 144.2 | 170.8 | 260.9 | |
Adj. book value per share | Rs | 96.8 | 112.9 | 138.3 | 163.8 | 260.9 | |
Shares outstanding (eoy) | m | 188.52 | 188.52 | 188.52 | 188.52 | 196.56 | |
Price / Sales ratio | x | 3.7 | 3.4 | 2.6 | 2.3 | 3.1 | |
Avg P/E ratio | x | 28.4 | 25.0 | 17.1 | 13.2 | 14.8 | |
P/CF ratio (eoy) | x | 23.6 | 20.0 | 14.3 | 11.0 | 12.7 | |
Price / Book Value ratio | x | 6.1 | 4.7 | 3.7 | 3.3 | 3.2 | |
Dividend payout | % | 18.5 | 17.9 | 17.5 | 23.5 | 24.7 | |
Avg Mkt Cap | Rs m | 115,452 | 105,079 | 101,459 | 105,343 | 164,818 | |
Total wages/salary | Rs m | 5,588 | 6,228 | 7,467 | 9,064 | 10,512 |
ALEMBIC PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 31,346 | 31,308 | 39,347 | 46,058 | 53,931 | |
Other income | Rs m | 26 | 349 | 271 | 139 | 875 | |
Total revenues | Rs m | 31,372 | 31,657 | 39,618 | 46,196 | 54,806 | |
Gross profit | Rs m | 6,147 | 6,153 | 8,558 | 11,704 | 14,801 | |
Depreciation | Rs m | 830 | 1,055 | 1,152 | 1,573 | 1,835 | |
Interest | Rs m | 52 | 34 | 184 | 272 | 160 | |
Profit before tax | Rs m | 5,291 | 5,413 | 7,493 | 9,998 | 13,681 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,222 | 1,204 | 1,568 | 1,992 | 2,533 | |
Profit after tax | Rs m | 4,069 | 4,209 | 5,926 | 8,006 | 11,148 | |
Gross profit margin | % | 19.6 | 19.7 | 21.8 | 25.4 | 27.4 | |
Effective tax rate | % | 23.1 | 22.2 | 20.9 | 19.9 | 18.5 | |
Net profit margin | % | 13.0 | 13.4 | 15.1 | 17.4 | 20.7 |
ALEMBIC PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 14,938 | 19,475 | 21,317 | 24,628 | 25,779 | |
Current liabilities | Rs m | 8,140 | 12,672 | 16,637 | 17,516 | 12,808 | |
Net working cap to sales | % | 21.7 | 21.7 | 11.9 | 15.4 | 24.1 | |
Current ratio | x | 1.8 | 1.5 | 1.3 | 1.4 | 2.0 | |
Inventory Days | Days | 14 | 13 | 10 | 10 | 23 | |
Debtors Days | Days | 4 | 6 | 5 | 7 | 2 | |
Net fixed assets | Rs m | 13,168 | 21,163 | 28,200 | 35,263 | 41,311 | |
Share capital | Rs m | 377 | 377 | 377 | 377 | 393 | |
"Free" reserves | Rs m | 18,646 | 21,824 | 26,811 | 31,817 | 50,883 | |
Net worth | Rs m | 19,023 | 22,201 | 27,188 | 32,194 | 51,276 | |
Long term debt | Rs m | 0 | 5,000 | 4,993 | 8,870 | 1,999 | |
Total assets | Rs m | 28,106 | 40,638 | 49,518 | 59,891 | 67,090 | |
Interest coverage | x | 102.2 | 160.2 | 41.7 | 37.8 | 86.4 | |
Debt to equity ratio | x | 0 | 0.2 | 0.2 | 0.3 | 0 | |
Sales to assets ratio | x | 1.1 | 0.8 | 0.8 | 0.8 | 0.8 | |
Return on assets | % | 14.7 | 10.4 | 12.3 | 13.8 | 16.9 | |
Return on equity | % | 21.4 | 19.0 | 21.8 | 24.9 | 21.7 | |
Return on capital | % | 28.1 | 20.0 | 23.9 | 25.0 | 26.0 | |
Exports to sales | % | 49.8 | 46.4 | 49.4 | 47.3 | 66.8 | |
Imports to sales | % | 10.3 | 10.5 | 15.4 | 13.2 | 12.7 | |
Exports (fob) | Rs m | 15,626 | 14,535 | 19,453 | 21,808 | 36,020 | |
Imports (cif) | Rs m | 3,241 | 3,288 | 6,065 | 6,062 | 6,845 | |
Fx inflow | Rs m | 15,806 | 14,722 | 19,453 | 21,808 | 36,020 | |
Fx outflow | Rs m | 5,289 | 7,026 | 6,065 | 6,062 | 6,845 | |
Net fx | Rs m | 10,517 | 7,696 | 13,388 | 15,746 | 29,175 |
ALEMBIC PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 3,286 | 3,124 | 8,120 | 4,492 | 14,634 | |
From Investments | Rs m | -4,859 | -8,844 | -7,556 | -7,316 | -8,388 | |
From Financial Activity | Rs m | -1,289 | 5,026 | 590 | 1,549 | -5,974 | |
Net Cashflow | Rs m | -2,862 | -693 | 1,153 | -1,272 | 262 |
Share Holding
Shareholding as on Mar 2022
|
Company Information
|
CHM: Chirayu Amin | COMP SEC: Charandeep Singh Saluja | YEAR OF INC: 2010 | BSE CODE: 533573 | FV (Rs): 2 | DIV YIELD (%): 1.9 |
More Pharmaceuticals Company Fact Sheets: SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN
Compare ALEMBIC PHARMA With: SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN
Indian share markets ended the week on a firm note tracking positive global cues.
In 2021, R&D of pharma companies roared to life in a never-before-seen way.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsWith India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Here's why shares of Tata Power have fallen in recent days.
Some sectors have corrected by 50%. Do they merit a look?
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
This is how you can tell the market is going to recover.
More